PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

PhaseBio Pharmaceuticals (Nasdaq: PHAS), a clinical-stage biopharmaceutical company, will participate in two virtual investor conferences. The Cowen 41st Annual Health Care Conference is scheduled for March 4, 2021, where CEO Jonathan P. Mow will join a panel discussion from 1:30 pm – 2:30 pm ET. The H.C. Wainwright Global Life Sciences Conference will take place on March 9, 2021, with Mow presenting a company overview on demand starting at 7:00 am ET. Webcasts will be available on PhaseBio's website for 90 days post-event.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the company will be participating in two upcoming virtual investor conferences. Details of the events are as follows:

• Cowen 41st Annual Health Care Conference
  Date: March 4, 2021
  Time: 1:30 pm – 2:30 pm ET
  Chief Executive Officer, Jonathan P. Mow, is scheduled to participate in a panel discussion

• H.C. Wainwright Global Life Sciences Conference
  Date: March 9, 2021
  Time: On demand beginning at 7:00 am ET
  Chief Executive Officer, Jonathan P. Mow, will present a company overview

Interested parties can access the live and archived webcasts of the virtual sessions on the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replays will be available for 90 days after the conclusion of the live presentations.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005652/en/

FAQ

What events will PhaseBio Pharmaceuticals participate in March 2021?

PhaseBio Pharmaceuticals will participate in the Cowen 41st Annual Health Care Conference on March 4, 2021, and the H.C. Wainwright Global Life Sciences Conference on March 9, 2021.

Who is presenting at the Cowen conference for PhaseBio?

CEO Jonathan P. Mow will participate in a panel discussion at the Cowen 41st Annual Health Care Conference.

When will PhaseBio's presentation be available for viewing?

The presentations will be available on demand on PhaseBio's website and will remain accessible for 90 days after the events.

What is the time of PhaseBio's participation in the Cowen conference?

PhaseBio will participate in the Cowen 41st Annual Health Care Conference from 1:30 pm to 2:30 pm ET on March 4, 2021.

What time will Jonathan P. Mow's presentation be available at the H.C. Wainwright conference?

Jonathan P. Mow's presentation at the H.C. Wainwright Global Life Sciences Conference will be available on demand starting at 7:00 am ET on March 9, 2021.